TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6734072

Group type: COMPARATOR
Intervention: Intravenous hydrocortisone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intraluminal hydrocortisone (100 mg/l)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intraluminal hydrocortisone (10 mg/l and 30 mg/l) followed by intravenous hydrocortisone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intraluminal hydrocortisone (100 mg/l) perfused with fructose and bicarbonate
Number of subjects: 16
Study: 31160222

Group type: EXPERIMENTAL
Intervention: Listening to music played three times a day for 3 days postoperatively
Number of subjects: 0
Study: 30321852

Group type: COMPARATOR
Intervention: Rigid boot with heel wedges
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Equinus cast
Number of subjects: 29
Study: 28033276

Group type: EXPERIMENTAL
Intervention: Automatic bladder irrigation device
Number of subjects: 146

Group type: COMPARATOR
Intervention: Traditional bladder irrigation
Number of subjects: 146
Study: 25227544

Group type: EXPERIMENTAL
Intervention: Position two wheelchair configuration (no seat slope, solid backrest mounted at 95 degree seat to back angle, solid seat insert with flat foam cushion)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Position one wheelchair configuration (one inch of seat slope, solid backrest mounted at 105 degree seat to back angle, no solid seat insert with gel/foam contoured cushion)
Number of subjects: 19
Study: 21868411

Group type: EXPERIMENTAL
Intervention: Fluoroscopy plus electrophysiological mapping (F + EP)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard fluoroscopy (F)
Number of subjects: 156
Study: 20083751

Group type: EXPERIMENTAL
Intervention: LC+LCBDE
Number of subjects: 122
Study: 17907481

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 5000 ppm fluoride (Duraphat)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dentifrice containing 1450 ppm fluoride (Caries Protection, control)
Number of subjects: 30
Study: 15738009

Group type: EXPERIMENTAL
Intervention: Misoprostol (0.25 microg intravaginally)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Dinoprostone (0.5 mg intracervically)
Number of subjects: 84
Study: 12941196

Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tumor embolization
Number of subjects: 0
Study: 10912884

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8836642

Group type: EXPERIMENTAL
Intervention: Standardized exercise challenge
Number of subjects: 17

Group type: COMPARATOR
Intervention: Histamine challenge
Number of subjects: 17

Group type: COMPARATOR
Intervention: Baseline lung function measurement without any challenge
Number of subjects: 17
Study: 1718243

Group type: EXPERIMENTAL
Intervention: 7.5% sodium chloride/dextran 70 (HSD)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 166
Study: 6981575

Group type: EXPERIMENTAL
Intervention: Propranolol (continuous oral administration, dosage reducing heart rate by 25%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31296586

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine, starting at 12 mg/day, titrated up to a maximum of 48 mg/day (36 mg/day for patients on strong CYP2D6 inhibitors).
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine
Number of subjects: 343
Study: 29862280

Group type: EXPERIMENTAL
Intervention: Programmed Intermittent Epidural Bolus (PIEB)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Continuous Epidural Infusion (CEI)
Number of subjects: 57
Study: 27255156

Group type: EXPERIMENTAL
Intervention: Treadmill-integrated ankle robotics
Number of subjects: 26

Group type: COMPARATOR
Intervention: Seated ankle robotics
Number of subjects: 26
Study: 24952685

Group type: EXPERIMENTAL
Intervention: Optimal LV lead position (n = 202)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Optimal LV lead position
Number of subjects: 250

Group type: COMPARATOR
Intervention: Suboptimal LV lead placement
Number of subjects: 250
Study: 22617579

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Combination (clomiphene citrate and metformin)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Control (non-ovulating women)
Number of subjects: 626
Study: 20650012

Group type: EXPERIMENTAL
Intervention: time‐contingent paracetamol (4 g daily in divided doses)
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: PRN paracetamol
Number of subjects: 1650

Group type: COMPARATOR
Intervention: double placebo
Number of subjects: 1650
Study: 17993030

Group type: EXPERIMENTAL
Intervention: Carbamide peroxide containing dentifrice (Rembrandt Plus)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluoride containing dentifrice (Close Up with fluoride)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Artificial saliva (control group)
Number of subjects: 30
Study: 15848538

Group type: EXPERIMENTAL
Intervention: Early cessation of corticosteroid therapy
Number of subjects: 397

Group type: COMPARATOR
Intervention: Long-term corticosteroid maintenance therapy
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Tacrolimus-based immunosuppressive regimen
Number of subjects: 397
Study: 11889372

Group type: EXPERIMENTAL
Intervention: Teleproctored endoscopic sinus surgery
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional endoscopic sinus surgery (control)
Number of subjects: 87
Study: 9785195

Group type: EXPERIMENTAL
Intervention: GnRH‐a/hMG
Number of subjects: 198

Group type: COMPARATOR
Intervention: hMG-only
Number of subjects: 198
Study: 7622004

Group type: EXPERIMENTAL
Intervention: Intensive therapy aimed at maintaining near-normal blood glucose values
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total glycemic exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-DCCT glycemic exposure (screening HbA1c value and IDDM duration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycemic exposure during the DCCT (mean HbA1c, time in study)
Number of subjects: 0
Study: 2143145

Group type: EXPERIMENTAL
Intervention: Long-acting GnRH-a administered in early follicular phase (group A)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Long-acting GnRH-a administered in midluteal phase (group B)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Both groups A and B
Number of subjects: 216
Study: 735925

Group type: EXPERIMENTAL
Intervention: Physostigmine (single dose)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Physostigmine (long-term treatment)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Physostigmine (sustained treatment for 6 months)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Physostigmine (sustained treatment for 6 to 36 months)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Methylscopolamine (control)
Number of subjects: 23
Study: 30796832

Group type: EXPERIMENTAL
Intervention: Preoperative denosumab
Number of subjects: 106
Study: 28926440

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 0 μg/ml
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 1 μg/ml
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 2 μg/ml
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Cumulative fentanyl dose
Number of subjects: 345
Study: 25060423

Group type: EXPERIMENTAL
Intervention: Facilitated tucking
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no facilitated tucking)
Number of subjects: 42
Study: 23415422

Group type: EXPERIMENTAL
Intervention: Azithromycin 1%
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone (gatifloxacin 0.3%, moxifloxacin 0.5%, ofloxacin 0.3%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (untreated fellow eye)
Number of subjects: 24
Study: 20632302

Group type: COMPARATOR
Intervention: Infrapatellar taping
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Quadriceps strengthening
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Quadriceps stretching
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combined treatments (taping, strengthening, stretching)
Number of subjects: 41
Study: 19589154

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 1420

Group type: EXPERIMENTAL
Intervention: Dietary intake assessment using FFQ
Number of subjects: 1420
Study: 17144784

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective serotonin-reuptake inhibitors
Number of subjects: 0
Study: 15138667

Group type: EXPERIMENTAL
Intervention: Active vitamin D3 analogues
Number of subjects: 0
Study: 11314283

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (AE + R)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Aerobic training alone (AE)
Number of subjects: 36
Study: 9455717

Group type: EXPERIMENTAL
Intervention: Midazolam with Erythromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam with Clarithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam with Azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam with Erythromycin or Clarithromycin
Number of subjects: 0
Study: 8187005

Group type: EXPERIMENTAL
Intervention: Additional four cycles of vinblastine/cisplatin after radiotherapy
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Six weekly doses of carboplatin concurrent with radiotherapy
Number of subjects: 91
Study: 3063506

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study: 31115690

Group type: EXPERIMENTAL
Intervention: Intrapapillary injection (IPI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inferior alveolar nerve block (IANB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both IPI and IANB
Number of subjects: 40
Study: 31573398

Group type: COMPARATOR
Intervention: 0.55 T MRI examinations
Number of subjects: 83

Group type: COMPARATOR
Intervention: 0.55 T MRI with metallic interventional devices
Number of subjects: 83

Group type: COMPARATOR
Intervention: MRI-guided right heart catheterization
Number of subjects: 83

Group type: COMPARATOR
Intervention: Oxygen inhalation during 0.55 T MRI
Number of subjects: 83

Group type: COMPARATOR
Intervention: Spiral image acquisitions at 0.55 T
Number of subjects: 83

Group type: COMPARATOR
Intervention: Representative imaging of brain, spine, abdomen, and heart at 0.55 T
Number of subjects: 83
Study: 28516509

Group type: EXPERIMENTAL
Intervention: Subthreshold depression (CES-D)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Subthreshold anxiety (HADS-A)
Number of subjects: 540
Study: 25929711

Group type: EXPERIMENTAL
Intervention: Chin cup treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 42
Study: 23521503

Group type: EXPERIMENTAL
Intervention: GSK239512 (5/10/20/40 μg and 10/20/40/80 μg regimens)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GSK239512 (20/40/80/150 μg regimen)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (in Part A and Part B)
Number of subjects: 18
Study: 21269308

Group type: EXPERIMENTAL
Intervention: LAB diet
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 19761874

Group type: EXPERIMENTAL
Intervention: RMET
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: IMT
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham-training
Number of subjects: 26
Study: 16875470

Group type: EXPERIMENTAL
Intervention: Contractubex gel
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no Contractubex gel)
Number of subjects: 120
Study: 15211871

Group type: EXPERIMENTAL
Intervention: Hyperthermia
Number of subjects: 0
Study: 11418912

Group type: EXPERIMENTAL
Intervention: Micro QuickAnchor (1.3 mm) using 3‐0 braided polyester with a modified 4‐strand Becker suture pattern
Number of subjects: 9

Group type: COMPARATOR
Intervention: Pullout button using 3‐0 monofilament nylon in a 2‐strand Bunnell suture pattern
Number of subjects: 9

Group type: COMPARATOR
Intervention: Mini QuickAnchor (1.8 mm) using 3‐0 braided polyester in a 2‐strand Bunnell suture pattern
Number of subjects: 9
Study: 9024032

Group type: EXPERIMENTAL
Intervention: Epidural dexamethasone (1 mL, 5 mg) with 25 mL 2% lidocaine and epinephrine 1:200,000
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (Group II) - no dexamethasone
Number of subjects: 1000
Study: 8395488

Group type: EXPERIMENTAL
Intervention: Low-dose Lisinopril
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3740389

Group type: EXPERIMENTAL
Intervention: Bupivacaine applied topically to the fallopian tubes and injected into the skin wounds
Number of subjects: 60

Group type: COMPARATOR
Intervention: No local anaesthetic (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 30412993

Group type: EXPERIMENTAL
Intervention: Nature-Based Therapy (NBT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Support Group Meetings (SGMs)
Number of subjects: 20
Study: 26154154

Group type: EXPERIMENTAL
Intervention: Vascular occlusion (OCC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sequential intermittent pneumatic compression (SIPC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Passive control (CON)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All conditions (OCC, SIPC, CON)
Number of subjects: 12
Study: 24473249

Group type: EXPERIMENTAL
Intervention: Rhythmic auditory-cued (RAC) overground walking
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Speed-dependent treadmill training (SDTT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 22019076

Group type: EXPERIMENTAL
Intervention: Olanzapine (10-20mg/day, n=169)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Quetiapine (300-700mg/day, n=174)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Both Olanzapine and Quetiapine
Number of subjects: 343
Study: 19827029

Group type: EXPERIMENTAL
Intervention: 5% extract of Solidago chilensis applied externally as a gel, two daily applications for 15 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo gel applied externally, two daily applications for 15 days
Number of subjects: 10
Study: 17823508

Group type: EXPERIMENTAL
Intervention: Regular dentifrices (1,500 ppm F)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Flavoured dentifrices for children (1,100 ppm F)
Number of subjects: 42
Study: 15775780

Group type: EXPERIMENTAL
Intervention: NOS3 haplotypes
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Four haplotypes accounting for 11.9% of all represented haplotypes
Number of subjects: 110
Study: 11975091

Group type: EXPERIMENTAL
Intervention: Reboxetine (2 x 2 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11471032

Group type: EXPERIMENTAL
Intervention: alpha‐IFN treatment
Number of subjects: 261

Group type: COMPARATOR
Intervention: Control group (adults)
Number of subjects: 261
Study: 8732235

Group type: EXPERIMENTAL
Intervention: Acarosan treatment and bedding covers
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Acarosan treatment
Number of subjects: 70
Study: 1374201

Group type: EXPERIMENTAL
Intervention: Diclofenac (0.35 mg.kg‐1 bolus followed by a constant‐rate infusion of 90 micrograms.min‐1 for 24 h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 40
Study: 3926667

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone (1 ml Decadronphosphate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31959019

Group type: EXPERIMENTAL
Intervention: Epinephrine HFA (2 × 125 mcg/inhalation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epinephrine CFC (2 × 220 mcg/inhalation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo HFA
Number of subjects: 0
Study: 30770780

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP) 0.5 mg/kg, i.v.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 46
Study: 29158148

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 57
Study: 27269942

Group type: EXPERIMENTAL
Intervention: Pertuzumab (840 mg loading dose followed by 420 mg every 3 weeks)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus chemotherapy
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Gemcitabine and paclitaxel cohorts
Number of subjects: 156
Study: 24198302

Group type: EXPERIMENTAL
Intervention: LY2605541
Number of subjects: 76

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 76
Study: 22873700

Group type: EXPERIMENTAL
Intervention: High-intensity intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-intensity intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 20383089

Group type: EXPERIMENTAL
Intervention: Reviewing the video and 10 minutes unsupervised practice
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (received the intervention after the scenario)
Number of subjects: 55
Study: 18405704

Group type: EXPERIMENTAL
Intervention: Fetal pulmonary artery (PA) diameters measurement
Number of subjects: 21
Study: 16472719

Group type: EXPERIMENTAL
Intervention: Alcohol ingestion (60 g of ethanol)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonalcoholic beverage (control)
Number of subjects: 100
Study: 12661144

Group type: EXPERIMENTAL
Intervention: Pulsatile tocolysis with Fenoterol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Continuous tocolysis with Fenoterol
Number of subjects: 24
Study: 10235107

Group type: EXPERIMENTAL
Intervention: Melatonin (1 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8918401

Group type: EXPERIMENTAL
Intervention: Oral levo-leucovorin (1-leucovorin) 25 mg/dose followed by oral 5-dFUR 750 mg/m2 twice daily for 4 days every 12 days (arm A)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) 1-leucovorin 25 mg/dose followed by i.v. 5-dFUR 3000 mg/m2 for 5 days every 21 days (arm B)
Number of subjects: 130
Study: 31451014

Group type: EXPERIMENTAL
Intervention: SYNERGY
Number of subjects: 1684

Group type: COMPARATOR
Intervention: PROMUS Element Plus
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: SYNERGY (Diabetes Substudy)
Number of subjects: 1684

Group type: COMPARATOR
Intervention: PROMUS Element Plus (Diabetes Substudy)
Number of subjects: 1684
Study: 28106568

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 2

Group type: COMPARATOR
Intervention: General Exercise (GE)
Number of subjects: 2
Study: 26229109

Group type: EXPERIMENTAL
Intervention: Joint mobilization and stretching exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stretching exercises alone
Number of subjects: 30
Study: 24468068

Group type: EXPERIMENTAL
Intervention: Asymmetric training program using virtual reality reflection equipment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Symmetric training program
Number of subjects: 24
Study: 23077192

Group type: EXPERIMENTAL
Intervention: Skim milk
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Whey
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Casein
Number of subjects: 203

Group type: COMPARATOR
Intervention: Water
Number of subjects: 203

Group type: COMPARATOR
Intervention: Pretest control group
Number of subjects: 203
Study: 18955429

Group type: EXPERIMENTAL
Intervention: Pre-operative physiotherapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no pre-operative physiotherapy)
Number of subjects: 23
Study: 15725200

Group type: EXPERIMENTAL
Intervention: Midwife-led brief counseling intervention (face-to-face within 72 hours of birth and telephone at 4-6 weeks postpartum)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no counseling intervention)
Number of subjects: 103
Study: 12733954

Group type: EXPERIMENTAL
Intervention: Unilateral Moore pharyngoplasty
Number of subjects: 18
Study: 11401042

Group type: EXPERIMENTAL
Intervention: Multiple chronic health problems (categories: 'No', 'Few', 'Some', 'A lot of')
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Low income and unemployment
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 4000
Study: 8971943

Group type: EXPERIMENTAL
Intervention: Heparin-coated ECC
Number of subjects: 200

Group type: COMPARATOR
Intervention: Uncoated ECC
Number of subjects: 200
Study: 1290729

Group type: EXPERIMENTAL
Intervention: Ketoprofen SR
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sulindac
Number of subjects: 80
Study: 2981515

Group type: EXPERIMENTAL
Intervention: Intermittent long-term combined chemotherapy (ILTCC) with immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous long-term combined chemotherapy (CLTCC) with immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short-term combined chemotherapy (STCC)
Number of subjects: 0
Study: 30978434

Group type: EXPERIMENTAL
Intervention: Infused autograft immune effector cells (macrophage type 1, macrophage type 2, dendritic cell type 1, dendritic cell type 2, myeloid-derived suppressor cells, CD4+PD-1-, CD4+PD-1+, CD8+PD-1-, CD8+PD-1+, lymphocyte to monocyte ratio, NKp30, KIR2DL2)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: A-LMR, MDSC, NKp30, KIR2DL2, lactate dehydrogenase
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: DC1, MDSC, NKp30, CD4+PD-1-, M2
Number of subjects: 111
Study: 29332737

Group type: EXPERIMENTAL
Intervention: Lateral glide MWM of the hip joint into flexion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo MWM
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 15